Phase 3 N=17 A Rho-kinase Inhibitor (Fasudil) in the Treatment of Raynaud's Phenomenon
Raynaud · Scleroderma
Primary: The Time to Recover 50% of Fall in the Baseline Skin Temperature. — 7.5; 8.2; 7.9 minutes
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=243 PF-00489791 For The Treatment Of Raynaud's
Raynaud's Disease · Peripheral Vascular Disease
Primary: Change From Baseline in Mean Raynaud's Condition Score (RCS) at Week 4 — 3.04; 2.90; 2.98; 3.14 units on a scale — p=0.6513
N/A N=26 Beet the Cold: The Effect of Inorganic Nitrate Supplementation in Individuals With Raynaud's Phenomenon
Raynaud Phenomenon
Primary: Peripheral Blood Flow — 3.7; 3.7; 4.1; 3.7 flux.mmHg-1
Phase 2 N=34 Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 2)
Raynaud Phenomenon Secondary to Systemic Sclerosis
Primary: Change in Frequency of Symptomatic RP Attacks — -14.32; -15.09 Number of RP attacks per week — p=0.8498
N/A N=10 Botulinum Toxin in the Treatment of Raynaud's
Raynaud's Syndrome
Primary: Mean Digital Temperature Difference From Baseline — 1.30 Celsius
N/A N=10 Tadalafil for the Treatment of Raynaud's
Raynaud
Primary: Number of Raynaud's Phenomenon Attacks Per Day — 2.4; 1.1; 2.0; 2.3 Raynaud's attacks per day
Phase 2 N=69 A Study to Investigate Safety of GS-248 and Efficacy on Raynauds' Phenomenon in Systemic Sclerosis
Systemic Sclerosis
Primary: Mean Change From Baseline to Week 4 in the Number of Raynaud Attacks Per Week. — -3.41; -4.22 number of attacks — p=<0.05
Phase 3 N=29 Efficacy Study of PDE-5 Inhibitor and Calcium Channel Inhibitor for the Treatment of Secondary Raynaud Phenomenon
Raynaud Phenomenon
Primary: RP Attacks Per Day — -0.5; -0.5 attacks per day
Phase 3 N=196 Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 3)
Raynaud's Phenomenon Secondary to Systemic Sclerosis
Primary: Change in Frequency of Symptomatic RP Attacks — -11.47; -12.73 Number of RP attacks per week — p=0.4210
Phase 2 N=12 Cold Challenge With C21 in RP
Raynaud Phenomenon · Systemic Sclerosis
Primary: Area Under the Curve for Rewarming of Each Finger After Cold Challenge (AUC) as Measured by Thermography — 19558.43; 20045.96 C*sec — p==0.3801
Phase 2 N=41 Efficacy and Tolerability of Ginkgo Biloba Extract in Patients With Raynaud´s Phenomenon
Raynaud Disease
Primary: Frequency of Vasospastic Attacks — 2.4; 2.0 attacks per day
Phase 2 N=65 Efficacy and Safety of Vascana® in Subjects With Secondary Raynaud's Phenomenon
Raynaud's Phenomenon Secondary to Connective Tissue Disease
Primary: Raynaud's Symptom Severity (Change From Baseline) — -20.19; -18.63 score on a scale
Phase 3 N=80 Efficacy of Botulinum Toxin In Scleroderma-Associated Raynaud's Syndrome
Scleroderma · Raynaud's Syndrome
Primary: Change in Digital Blood Flow From Pre- to Post-injection. — -36.19; -6.10 Blood flow, measured in LDI flux units,
Phase 2 N=24 Atorvastatin for Microvascular Endothelial Function and Raynaud in Early Diffuse Scleroderma
Scleroderma
Primary: Proportion of Patients Improving Their EndoPAT Reactive Hyperemia Index (RHI) at the End-of-study (16 Weeks) — 6; 4 Participants
N/A N=20 Efficacy of Ambrisentan in Limited Scleroderma Patients in Improving Blood Flow to Hands or Feet
Ischemia
Primary: Digital Micro-vascular Flow — .11; .18; -.01; -.06 perfusion unit
Phase 2 N=48 A Two-Part Study of BOTOX® Therapy for Ischemic Digits
Raynaud's Disease
Primary: Percentage of Patient Reported Pain-free Days — 12; 48 percentage of pain free days
Phase 3 N=41 Effect of Sildenafil on the Microcirculatory Blood Flow and Endothelial Progenitor Cells in Systemic Sclerosis
Scleroderma, Systemic · Scleroderma, Diffuse · Scleroderma, Limited
Primary: Digital Skin Microvascular Blood Flow Measured by Laser Doppler Imaging (LDI) Before Cold Stimulus — 260.0; 246.3 perfusion units
N/A N=24 Nasal Physiologic Reactivity of Nonallergic Rhinitics to Cold Air Provocation
Vasomotor Rhinitis
Primary: Net Proportional Change in Nasal Airway Resistance — 0.11; 0.04 proportional change (unit-less)
N/A N=27 Hands on - a Hand Care Guide in Systemic Sclerosis
Scleroderma
Primary: Cochin Hand Functional Scale — 19.24 units on a scale
Phase 3 N=47 Effects of Ranolazine on Coronary Flow Reserve in Symptomatic Diabetic Patients and CAD
Diabetes, Type I · Diabetes, Type II · Angina
Primary: Change in Post-exercise Coronary Vasodilator Reserve — -4; 2 % change
Phase 2 N=19 IL1-TRAP, Rilonacept, in Systemic Sclerosis
Scleroderma · Systemic Sclerosis · Diffuse Scleroderma
Primary: Change in 2- Gene Biomarker — -2.67; 0.42 2- gene biomarkers score
Phase 2 N=121 Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis
Scleroderma, Systemic
Primary: Change From Baseline in Modified Rodnan Skin Score (mRSS) to Week 52 — -2.088; -0.769 score on a scale — p=0.0815
Phase 2 N=57 Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)
Systemic Sclerosis-Associated PAH
Primary: Change From Baseline in Distance Walked During a Six Minute Walk Test — 23.6; 0.5 Meters — p=0.12
N/A N=25 Apollo Device for Fatigue in Systemic Sclerosis
Systemic Sclerosis · Fatigue · Raynaud Phenomenon
Primary: Change in PROMIS® Item Bank v1.0 - Fatigue - Short Form 13a (FACIT-Fatigue) at 4 Weeks (End-of-Study) Compared to Baseline — -7.0; 62.5 T-score — p=<0.001
Phase 2 N=34 Vericiguat in Patients With Metabolic Syndrome and Coronary Vascular Dysfunction
Metabolic Syndrome · Coronary Microvascular Dysfunction
Primary: Absolute Change in Coronary Cross-sectional Area (in mm²) Within the Vericiguat Group as Assessed by Magnetic Resonance Imaging (MRI) — -1.11; 0.40 mm^2 — p=0.0005